Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy and Safety of Oral Febuxostat in Participants With Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2007-02-01

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 2269

Registration Number: NCT00430248

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

Phase 4

Completed

Conditions: Chronic Insomnia

Interventions: Drug: Placebo
Drug: Ramelteon

First Posted Date: 2006-12-21

Last Posted Date: 2016-06-28

Lead Sponsor: Takeda

Target Recruit Count: 552

Registration Number: NCT00414102

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2006-11-03

Last Posted Date: 2013-03-27

Lead Sponsor: Takeda

Target Recruit Count: 655

Registration Number: NCT00395512

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

Phase 2

Completed

Conditions: Neuralgia, Postherpetic

Interventions: Drug: TAK-583
Drug: Placebo

First Posted Date: 2006-09-18

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 399

Registration Number: NCT00377598

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: Type 2 Diabetes

Interventions: Drug: Pioglitazone and Azilsartan
Drug: Pioglitazone

First Posted Date: 2006-09-14

Last Posted Date: 2010-06-22

Lead Sponsor: Takeda

Target Recruit Count: 96

Registration Number: NCT00376181

Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Parathyroid Hormone (PTH)
Drug: Risedronate

First Posted Date: 2006-08-17

Last Posted Date: 2012-08-20

Lead Sponsor: Takeda

Target Recruit Count: 407

Registration Number: NCT00365456

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Azilsartan Medoxomil
Drug: Olmesartan

First Posted Date: 2006-08-09

Last Posted Date: 2011-04-19

Lead Sponsor: Takeda

Target Recruit Count: 449

Registration Number: NCT00362115

Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

Phase 3

Completed

Conditions: GERD

Interventions: Drug: Pantoprazole

First Posted Date: 2006-06-13

Last Posted Date: 2012-05-07

Lead Sponsor: Takeda

Target Recruit Count: 628

Registration Number: NCT00336219

Locations: 🇭🇺
Altana Pharma/Nycomed, Vác, Hungary

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone
Drug: Rosiglitazone

First Posted Date: 2006-05-31

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 719

Registration Number: NCT00331487

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin placebo
Drug: Alogliptin
Drug: Pioglitazone placebo
Drug: Pioglitazone

First Posted Date: 2006-05-22

Last Posted Date: 2013-04-04

Lead Sponsor: Takeda

Target Recruit Count: 1554

Registration Number: NCT00328627

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy